Department of Planning and Budget 2024 Session Fiscal Impact Statement

l •	BIII Numbe	пвэтэ	
	House of Orig		
	Second House	☐ In Committee ☐ Substitute ☐ Enrolled	
2.	Patron:	ppe	
3.	Committee:	bor and Commerce	
١.	Title:	ate plan for medical assistance services and health insurance; pediatric	С

5. Summary: Directs the Board of Medical Assistance Services to amend the state plan for medical assistance services to include a provision for payment of medical assistance for the prophylaxis, diagnosis, and treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS) that includes payment for treatment using antimicrobials, medication and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin therapy.

The bill also requires each insurer proposing to issue individual or group accident and sickness insurance policies providing hospital, medical and surgical, or major medical coverage on an expense-incurred basis; each corporation providing individual or group accident and sickness subscription contracts; and each health maintenance organization providing a health care plan for health care services to provide coverage for the prophylaxis, diagnosis, and treatment of PANDAS and PANS. The bill requires such coverage to include treatment using antibiotics, medication, and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin therapy. The bill prohibits an insurer, corporation, or organization from (i) denying or delaying the coverage of PANDAS or PANS because the enrollee previously received treatment or because the enrollee was diagnosed with or received treatment for his condition under a different diagnostic name, including autoimmune encephalopathy; (ii) limiting coverage of immunomodulating therapies for the treatment of PANDAS or PANS in a manner that is inconsistent with the treatment guidelines developed by a consortium convened for the purposes of researching, identifying, and publishing best practice standards for diagnosis and treatment of PANDAS or PANS that are accessible for medical professionals and are based on evidence of positive patient outcomes; (iii) requiring a trial of therapies that treat only neuropsychiatric symptoms before authorizing coverage of immunomodulating therapies for the treatment of PANDAS or PANS; or (iv) denying coverage for out-of-state treatment if the service is not available within the Commonwealth.

6. Budget Amendment Necessary: Yes, Item 469 of HB 30 for the general fund cost to the state health insurance plan.

7. Fiscal Impact Estimates: Preliminary – see Item 8.

Expenditure Impact:

Fiscal Year	Dollars	Positions	Fund
2024	\$0	0.00	-
2025	\$792,000	0.00	GF
2025	\$792,000	0.00	NGF
2026	\$792,000	0.00	GF
2026	\$792,000	0.00	NGF

8. Fiscal Implications: According to the Department of Human Resource Management, the proposed legislation is expected to have an annual fiscal impact of 1,584,000. The projected cost will provide coverage for the prophylaxis, diagnosis, and treatment of PANDAS and PANS through the state health insurance plan.

According to the Department of Medical Assistance Services, the cost of this proposal is indeterminate but expected to be minimal. The department assumes that treatments currently associated with PANS and PANDAS are already covered in Medicaid and FAMIS, including behavioral therapies. However, PANS and PANDAS do not have specific diagnosis code and future treatment protocols are unknown. To the extent any of these potential treatments are utilized because of the bill, then additional costs may be incurred.

- **9. Specific Agency or Political Subdivisions Affected:** Department of Human Resource Management and Department of Medical Assistance Services
- 10. Technical Amendment Necessary: No.
- 11. Other Comments: None.